| All Releases |
|---|
 |
EpiCept Announces Results of Annual Meeting of Stockholders
Jul 3, 2009
|
13.0 KB
|
| |
TARRYTOWN, N.Y., Jul 03, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today the results of its 2009 Annual Meeting of Stockholders held on
June 2, 2009 in Stockholm, Sweden. The meeting was adjourned in order to
provide the company time to secure additional pr...
|
|
|
EpiCept Shares on the OMX Nordic Exchange Transferred Back to Ordinary Position from Observation Segment
Jun 29, 2009
|
11.2 KB
|
| |
TARRYTOWN, N.Y., Jun 29, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that its common stock traded on the OMX Nordic Exchange in
Stockholm has been removed from the observation segment and transferred
back to its ordinary position on the Exchange as of t...
|
|
|
EpiCept Announces Pricing of Public Offering
Jun 19, 2009
|
12.4 KB
|
| |
TARRYTOWN, N.Y., Jun 19, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today that it entered into definitive agreements for the purchase of
approximately 12.0 million shares of its common stock at $.80 per share
and two-and-one-half-year warrants to purchase up...
|
|
|
EpiCept Corporation to Present at the 5th Annual Noble Financial Equity Conference
Jun 5, 2009
|
11.4 KB
|
| |
TARRYTOWN, N.Y., Jun 05, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Jack Talley, President and CEO, will be presenting at the
5th Annual Noble Financial Equity Conference on Tuesday, June
9, 2009 at 8:40 a.m. Eastern Time. The conference will be h...
|
|
|
EpiCept Releases New Data Demonstrating Long-Term Durability of Ceplene in Sustaining Leukemia-Free Survival
Jun 4, 2009
|
12.3 KB
|
| |
TARRYTOWN, N.Y., Jun 04, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) has released
new long-term data showing that the use of Ceplene(R)
when administered in conjunction with low-dose interleukin-2 (IL-2)
provides durable protection from leukemia relapse in patients wit...
|
|
|
EpiCept Partners With IDIS For Ceplene(R) Named Patient/Compassionate Use Program
Jun 2, 2009
|
14.2 KB
|
| |
TARRYTOWN, N.Y., Jun 02, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it has signed an agreement with IDIS, a private,
U.K.-based company, to administer a Named Patient Program for Ceplene(R),
EpiCept's proprietary therapy approved in the European U...
|
|
|
EpiCept Announces Webcast of Annual Meeting of Stockholders
May 29, 2009
|
11.5 KB
|
| |
TARRYTOWN,N.Y., May 29, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that its annual meeting of stockholders will be accessible to
investors via webcast. The annual meeting will be held on June 2, 2009
at 4:00pm Stockholm time (10:00 am Eastern time) at ...
|
|
|
EpiCept Announces Presentation of New Crinobulin Data at 2009 American Society of Clinical Oncology Annual Meeting
May 28, 2009
|
12.3 KB
|
| |
TARRYTOWN, N.Y., May 28, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will present data from its Phase Ia trial of
crinobulin at the 45th Annual Meeting of the American Society
of Clinical Oncology (ASCO), taking place May 29 to June 2, 2009 in
...
|
|
|
EpiCept Corporation Reports First Quarter 2009 Operating and Financial Results
May 7, 2009
|
22.9 KB
|
| |
TARRYTOWN, N.Y., May 07, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced operating and financial results for the three months ended
March 31, 2009. For the first quarter of 2009, EpiCept's loss from
operations, before other expense and income taxes, was $4....
|
|
|
EpiCept to Report First Quarter 2009 Operating and Financial Results on May 7, 2009
May 1, 2009
|
11.3 KB
|
| |
TARRYTOWN, N.Y., May 01, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will host a conference call to discuss first quarter
2009 operating and financial results on Thursday, May 7, 2009 at 9:00
a.m. Eastern time. The call will follow the release o...
|
|
|
Notice of the Annual Meeting of Stockholders of EpiCept Corporation
Apr 30, 2009
|
15.5 KB
|
| |
TARRYTOWN, N.Y., Apr 30, 2009 (BUSINESS WIRE) -- Regulatory News:
With this notice, stockholders of EpiCept Corporation (Nasdaq and OMX
Nordic Exchange: EPCT) are invited to the Annual Meeting of Stockholders
(the "Annual Meeting") on June 2, 2009, at 4:00 p.m. Stockholm time
(10:00 a.m. Eastern time) at the Summit Grev Tur...
|
|
|
EpiCept Appoints Recognized Oncology Expert and Pharmaceutical Industry Leader as New Independent Board Member
Apr 13, 2009
|
11.9 KB
|
| |
TARRYTOWN, N.Y., Apr 13, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today the appointment of A. Collier Smyth, M.D., former senior vice
president of medical strategy - oncology at Bristol-Myers Squibb Company
(BMS), to its Board of Directors.
Prior to his r...
|
|
|
EpiCept Corporation Reports Fourth Quarter and Full Year 2008 Operating and Financial Results
Feb 27, 2009
|
24.4 KB
|
| |
TARRYTOWN, N.Y., Feb 27, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced operating and financial results for the fourth quarter and
year ended December 31, 2008. EpiCept's net loss for the fourth quarter
was $5.4 million, or $0.07 per share, and for the yea...
|
|
|
EpiCept to Report Fourth Quarter and Full Year 2008 Operating and Financial Results on February 27, 2009
Feb 23, 2009
|
11.3 KB
|
| |
TARRYTOWN, N.Y., Feb 23, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that it will host a conference call to discuss fourth quarter
and full year 2008 operating and financial results on Friday, February
27, 2009 at 9:00 a.m. Eastern time. The call will f...
|
|
|
EpiCept Announces Debt Repayment
Feb 23, 2009
|
10.4 KB
|
| |
TARRYTOWN, N.Y., Feb 23, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today that it has repaid the outstanding principal balance, together
with all remaining fees, of its $10 million senior secured debt facility
with Hercules Technology Growth Corporation. The...
|
|
|
EpiCept AnnouncesEPC2407 Generic Name is Crinobulin
Feb 23, 2009
|
11.4 KB
|
| |
TARRYTOWN, N.Y., Feb 23, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that the United States Adopted Names Council (USAN) has
approved "crinobulin" as the generic name for EPC2407, the company's
novel, small molecule vascular disruption agent (VDA) and a...
|
|
|
EpiCept Corporation to Present at the 11th Annual BIO CEO & Investor Conference
Feb 5, 2009
|
10.7 KB
|
| |
TARRYTOWN, N.Y., Feb 05, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Jack Talley, President and CEO, will be presenting at the
11th Annual BIO CEO & Investor Conference on February 10,
2009 at 2:15 p.m. Eastern Time at The Waldorf-Astoria Hotel in ...
|
|
|
EpiCept Corporation Announces Pricing of Public Offering
Feb 4, 2009
|
12.7 KB
|
| |
TARRYTOWN, N.Y., Feb 04, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today the pricing of a public offering of $25.0 million principal
aggregate amount of 7.5556% convertible senior subordinated notes due
February 2014 and five and one-half year warrants to p...
|
|
|
EpiCept Announces Resignation of Board Member
Feb 4, 2009
|
10.6 KB
|
| |
TARRYTOWN, N.Y., Feb 04, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
that John F. Bedard has resigned from the Company's Board of Directors,
effective February 3, 2009, solely because of a family health reason.
Mr. Bedard was a member of EpiCept's Board since...
|
|
|
EpiCept Receives Permission to File Ceplene(R) NDA
Feb 2, 2009
|
13.9 KB
|
| |
TARRYTOWN, N.Y., Feb 02, 2009 (BUSINESS WIRE) -- Regulatory News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced
today that the U.S. Food and Drug Administration (FDA) indicated that
the Company has the necessary pivotal data to file a New Drug
Application (NDA) for Ceplene(R) (histamine dihydrochlorid...
|
|
|
